Innoviva Q2 Revenue $119.6M, Net Product Sales +46%; Launches Nortiva Bio
Innoviva, Inc. reported strong financial results for the second quarter ended June 30, 2026, with total revenue increasing 19% year-over-year to $119.6 million and net product sales growing 46% to $51.8 million. Despite operational strength, the company recorded a net loss of $83.4 million, primarily driven by $161.0 million in unfavorable fair value changes in equity and long-term investments. Strategically, Innoviva launched Nortiva Bio, a new wholly-owned subsidiary focused on novel extended-release drug delivery, and entered a licensing agreement with Dr. Reddy’s Laboratories for XACDURO® in emerging markets. The company also continued its share repurchase program, buying back $31.4 million in shares during the quarter.
Key Highlights
- Total revenue for Q2 2026 was $119.6 million, representing 19% year-over-year growth.
- Net product sales reached $51.8 million, a 46% increase compared to Q2 2025.
- U.S. net product sales grew 26% year-over-year to $36.6 million.
- The company reported a net loss of $83.4 million, primarily due to $161.0 million in unfavorable investment fair value changes.
- Innoviva launched Nortiva Bio, a wholly-owned subsidiary focused on long-acting oral drug delivery technology.
- An exclusive licensing agreement for XACDURO® was signed with Dr. Reddy’s Laboratories for emerging markets.
- Innoviva repurchased 1.4 million shares for $31.4 million during Q2 2026 under its share repurchase program.
- Cash and cash equivalents totaled $570.4 million as of June 30, 2026.
Price Impact
More from INVA